Amivantamab Regimen Maintains EGFR-Like Safety Profile in Metastatic CRC

In an interview with Targeted Oncology, Filippo Pietrantonio, MD, discusses the safety and toxicity management of amivantamab (Rybrevant) plus chemotherapy for patients with metastatic colorectal cancer.

Watch part 1, part 2, and part 3 of Dr Pietrantonio’s interview.

As reported in updated data from the phase 1b/2 OrigAMI-1 study (NCT05379595), the overall safety profile of the combination is manageable and mirrors the experiences clinicians already have when using first-generation EGFR inhibitors combined with chemotherapy. Specifically, the rate of skin toxicity observed with this combination is in line with the rates seen for standard treatments like cetuximab (Erbitux) or panitumumab (Vectibix).

A key finding is that the addition of amivantamab does not result in an apparent increase in chemotherapy-related toxicities, particularly hematological adverse events (AEs). While MET inhibition introduces specific AEs such as peripheral edema and hypoalbuminemia, the incidence of high-grade events is notably low; only 2 cases of grade 3 or higher AEs related to these symptoms were recorded in the study. Dr Pietrantonio notes that these are manageable through proactive monitoring.

Read the full interview here.